Ecological Behavior of 6 Coxsackie B and 29 Echo Serotypes as Revealed by Serologic Survey of General Population in Aomori, Japan

Sato, Nobutake; Sato, Hiroyasu; Kawana, Rinji; Matumoto, Minoru

doi:10.7883/yoken1952.25.355

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to HPeV1, both seroepidemiological studies performed between 1965 and 2002 and this study, indicated that HPeV1 affects young people and that HPeV1 has been consistently endemic in Japan over the last 50 years . Data from NESID, which show that HPeV1 has been detected every year since surveillance started in 1981, also support the notion that HPeV1 has been endemic over the past few decades in Japan .…”

supporting

confidence: 77%

“…We had previously accidently detected HPeV3 in nasopharyngeal specimens from four children enrolled in this study (14), having collected the serum specimens prior to HPeV3 detection in two children with NT Ab titers <1:8. With regard to HPeV1, both seroepidemiological studies performed between 1965 and 2002 and this study, indicated that HPeV1 affects young people and that HPeV1 has been consistently endemic in Japan over Seroepidemiology of HPeVs 1,3 and 6 the last 50 years (19)(20)(21)(22). Data from NESID, which show that HPeV1 has been detected every year since surveillance started in 1981, also support the notion that HPeV1 has been endemic over the past few decades in Japan (23).…”

mentioning

confidence: 51%

See 1 more Smart Citation

Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014

Tanaka

Aoki

Matoba

et al. 2016

Microbiology and Immunology

View full text Add to dashboard Cite

To clarify the seroepidemiology of human parechovirus type 1 (HPeV1), 3 and 6, neutralizing antibodies (NT Abs) were measured in 214 serum specimens collected in 2014 in Yamagata, Japan. The seroprevalence against HPeV1 was 100% in all age groups, while that against HPeV3 and HPeV6 was 79.4% and 66.8%, respectively, overall. The geometric mean titers of NT Abs against HPeV1, 3 and 6 were 755.2, 255.0 and 55.9, respectively, overall. Our findings indicate that HPeV1 is the most prevalent HPeV circulating in Yamagata, followed by HPeV3 and HPeV6.

show abstract

supporting

confidence: 77%

mentioning

confidence: 51%

Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014

Tanaka

Aoki

Matoba

et al. 2016

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…HPeV1 infections are common and occur early in childhood, as was observed in this and other studies under taken in different countries [Nakao et al, 1970;Sato et al, 1972;Grist et al, 1978;Ehrnst and Eriksson, 1993]. Survival analysis was used to assess the incidence of HPeV1 infection in different age groups, since the follow up time for these children varied from 6 to 72 months.…”

Section: Discussionmentioning

confidence: 86%

Human parechovirus 1 infections in young children—no association with type 1 diabetes

Tauriainen

Martiskainen

Oikarinen

et al. 2007

Journal of Medical Virology

View full text Add to dashboard Cite

The epidemiology, transmission and clinical symptoms of human parechoviruses [HPeV, classified earlier as enteroviruses; echovirus 22 (HPeV1) and echovirus 23 (HPeV2)] remain poorly characterized. Enteroviruses and one parechovirus species, the Ljungan virus, have been associated with type 1 diabetes in humans and rodents. The occurrence of human parechovirus 1 (HPeV1) infections in young children and their possible association with type 1 diabetes was evaluated. The prospective birth cohort study comprised 221 Finnish children carrying genetic type 1 diabetes susceptibility and who were observed from birth. Thirty-four children developed multiple diabetes-associated autoantibodies, and 18 children progressed to clinical type 1 diabetes during the follow-up. HPeV1 infections were diagnosed by measuring neutralizing antibodies from the follow-up sera taken every 3-12 months. In addition, viral RNA was analysed by RT-PCR from stool samples taken every month from six of the participants. HPeV1 infections were found to occur early in childhood. The median age of infection was 18 months and 20% of the children had had an infection by the age of 1 year. The number of infections started to increase from the age of 6 months and most children had their first infection by 36 months. Nearly all (99%) mothers were HPeV1 antibody positive. No difference was found in infection frequency between boys and girls, nor between prediabetic, diabetic and control subjects. Most infections (87%) occurred during autumn, winter and spring.

show abstract

“…The major clinical symptoms of HPeV-1 and HPeV-2 infections have been reported to be gastrointestinal and respiratory, with fewer central nervous system (CNS) symptoms (Birenbaum et al, 1997;Ehrnst & Eriksson, 1993;Nakao & Miura, 1970;Sato et al, 1972;Hynes, 1992). HPeV-1 has also been associated with an outbreak of acute flaccid paralysis in Jamaica in 1986 (Figueroa et al, 1989) and with encephalitis in a 5-month-old boy in Finland (Koskiniemi et al, 1989).…”

Section: Discussionmentioning

confidence: 99%

Isolation and identification of a novel human parechovirus

Ito

Yamashita

Tsuzuki

et al. 2004

Journal of General Virology

236

269

View full text Add to dashboard Cite

A cytopathic agent (A308/99) was isolated using Vero cells from a stool specimen of a 1-year-old patient with transient paralysis. The agent was approximately 28 nm in diameter with a distinct ultrastructure resembling the virus particle of an enterovirus. It could not be neutralized by antisera against human picornaviruses such as human enterovirus, Aichi virus or human parechovirus. The virion contained three capsid proteins with molecular masses of 38, 30?3 and 30 kDa. Determination of the complete nucleotide sequence of A308/99 revealed that the nucleotide and deduced amino acid sequences were closely related to those of human parechoviruses. When 11 regions encoding the structural and non-structural proteins were compared, A308/99 had between 75 and 97 % and 73 and 97 % nucleotide identity with human parechovirus type 1 (HPeV-1) and type 2 (HPeV-2), respectively. The most distinctive divergence was seen in VP1, which had 74?5 % and 73?1 % nucleotide identity with HPeV-1 and HPeV-2, respectively. Viruses related to A308/99 were also isolated from three patients with gastroenteritis, exanthema or respiratory illnesses. A308/99 and these other three isolates had no arginine-glycine-aspartic acid (RGD) motif, which is located near the C terminus of VP1 in HPeV-1 and HPeV-2. A seroepidemiological study revealed that the prevalence of A308/99 antibodies was low (15 %) among infants but became higher with age, reaching more than 80 % by 30 years of age. These observations indicate that A308/99 is genetically close to, but serologically and genetically distinct from, HPeV-1 and HPeV-2 and accordingly can be classified as third serotype of human parechovirus.

show abstract

Ecological Behavior of 6 Coxsackie B and 29 Echo Serotypes as Revealed by Serologic Survey of General Population in Aomori, Japan

Cited by 14 publications

References 19 publications

Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014

Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014

Human parechovirus 1 infections in young children—no association with type 1 diabetes

Isolation and identification of a novel human parechovirus

Contact Info

Product

Resources

About